199 related articles for article (PubMed ID: 26086572)
1. In vitro susceptibilities of clinical isolates of carbapenemase-producing Enterobacteriaceae to fosfomycin and tigecycline.
Choudhury S; Yeng JL; Krishnan PU
Clin Microbiol Infect; 2015 Oct; 21(10):e75-6. PubMed ID: 26086572
[No Abstract] [Full Text] [Related]
2. In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents.
Hsu MS; Liao CH; Liu CY; Yang CJ; Huang YT; Hsueh PR
Int J Antimicrob Agents; 2011 Mar; 37(3):276-8. PubMed ID: 21269811
[No Abstract] [Full Text] [Related]
3. In-vitro susceptibility to colistin and tigecycline in New Delhi metallo-beta-lactamase-1 producing Enterobacteriaceae.
Chandran SP; Nagaraj S; Kalal BS; Muralidharan S; Macaden R
Indian J Med Microbiol; 2013; 31(4):419-20. PubMed ID: 24064660
[No Abstract] [Full Text] [Related]
4. In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae.
Berçot B; Poirel L; Dortet L; Nordmann P
J Antimicrob Chemother; 2011 Oct; 66(10):2295-7. PubMed ID: 21807739
[TBL] [Abstract][Full Text] [Related]
5. Identification of Enterobacteriaceae isolates with OXA-48 and coproduction of OXA-181 and NDM-1 in Norway.
Samuelsen Ø; Naseer U; Karah N; Lindemann PC; Kanestrøm A; Leegaard TM; Sundsfjord A
J Antimicrob Chemother; 2013 Jul; 68(7):1682-5. PubMed ID: 23463214
[No Abstract] [Full Text] [Related]
6. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
Garau J
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.
Vasoo S; Cunningham SA; Cole NC; Kohner PC; Menon SR; Krause KM; Harris KA; De PP; Koh TH; Patel R
Antimicrob Agents Chemother; 2015 Dec; 59(12):7842-6. PubMed ID: 26392487
[TBL] [Abstract][Full Text] [Related]
8. A pediatric case of New Delhi metallo-β-lactamase-1-producing Enterobacteriaceae in the United States.
Green DA; Srinivas N; Watz N; Tenover FC; Amieva M; Banaei N
Pediatr Infect Dis J; 2013 Nov; 32(11):1291-4. PubMed ID: 23743543
[TBL] [Abstract][Full Text] [Related]
9. Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England.
Hope R; Warner M; Potz NA; Fagan EJ; James D; Livermore DM
J Antimicrob Chemother; 2006 Dec; 58(6):1312-4. PubMed ID: 17035342
[No Abstract] [Full Text] [Related]
10. In vitro activity of tigecycline against metallo-beta-lactamase-producing Enterobacteriaceae.
Pliatsika V; Afkou Z; Protonotariou E; Sofianou D
J Antimicrob Chemother; 2007 Dec; 60(6):1406-7. PubMed ID: 17962216
[No Abstract] [Full Text] [Related]
11. Fosfomycin: an oral agent for urinary infection caused by extended spectrum beta-lactamase producing organisms.
Hutley EJ; Chand MA; Hounsome G; Kelsey MC
J Infect; 2010 Apr; 60(4):308-9. PubMed ID: 20114062
[No Abstract] [Full Text] [Related]
12. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
[TBL] [Abstract][Full Text] [Related]
13. Emergence of NDM-1- and IMP-14a-producing Enterobacteriaceae in Thailand.
Rimrang B; Chanawong A; Lulitanond A; Wilailuckana C; Charoensri N; Sribenjalux P; Phumsrikaew W; Wonglakorn L; Kerdsin A; Chetchotisakd P
J Antimicrob Chemother; 2012 Nov; 67(11):2626-30. PubMed ID: 22796889
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of tigecycline against extended-spectrum β-lactamase-producing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study.
Silva-Sanchez J; Reyna-Flores F; Velazquez-Meza ME; Rojas-Moreno T; Benitez-Diaz A; Sanchez-Perez A;
Diagn Microbiol Infect Dis; 2011 Jun; 70(2):270-3. PubMed ID: 21596226
[TBL] [Abstract][Full Text] [Related]
15. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Lu CT; Chuang YC; Sun W; Liu YC; Cheng YJ; Lu PL; Chen CM; Hsu GJ; Jang TN; Lee CM; Chiang PC; Shi ZY; Wang LS; Kung HC; Lin HC; Liao CH; Liu JW; Huang CH; Tsao SM; Hsueh PR
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S179-83. PubMed ID: 19013351
[TBL] [Abstract][Full Text] [Related]
16. Dissemination of carbapenemase-producing Enterobacteriaceae in France, 2012.
Dortet L; Cuzon G; Nordmann P
J Antimicrob Chemother; 2014 Mar; 69(3):623-7. PubMed ID: 24275115
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and mechanisms of resistance to carbapenems in Enterobacteriaceae isolates from 24 hospitals in Belgium.
Huang TD; Berhin C; Bogaerts P; Glupczynski Y;
J Antimicrob Chemother; 2013 Aug; 68(8):1832-7. PubMed ID: 23557926
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activity of tigecycline against enterobacteria producing two or more extended-spectrum beta-lactamases.
Vázquez MF; Romero ED; García MI; Rodríguez JA; Bellido JL
Int J Antimicrob Agents; 2008 Dec; 32(6):541-3. PubMed ID: 18789848
[No Abstract] [Full Text] [Related]
19. Trends in carbapenemase-producing Enterobacteriaceae, France, 2012 to 2014.
Dortet L; Cuzon G; Ponties V; Nordmann P
Euro Surveill; 2017 Feb; 22(6):. PubMed ID: 28205502
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
Morosini MI; García-Castillo M; Coque TM; Valverde A; Novais A; Loza E; Baquero F; Cantón R
Antimicrob Agents Chemother; 2006 Aug; 50(8):2695-9. PubMed ID: 16870760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
